Related Experiment Videos
Long-term colchicine treatment in children with familial Mediterranean fever
1Department of Medicine, Heller Institute of Medical Research, Sheba Medical Center, Tel-Hashomer, Israel.
Insights
Long-term colchicine treatment for childhood familial Mediterranean fever (FMF) led to high remission rates for febrile attacks and arthritis. This therapy prevented amyloidosis and had no significant adverse effects on growth or fertility, highlighting the importance of early FMF diagnosis.
Area of Science:
- Pediatric Rheumatology
- Genetics
- Internal Medicine
Background:
- Familial Mediterranean fever (FMF) is a genetic autoinflammatory disorder characterized by recurrent febrile episodes.
- Childhood-onset FMF poses risks of chronic inflammation, arthritis, and potentially life-threatening amyloidosis.
- Long-term prophylactic treatment is crucial for managing FMF in pediatric populations.
Purpose of the Study:
- To evaluate the long-term efficacy and safety of continuous colchicine prophylaxis in children with FMF.
- To assess the impact of colchicine on febrile attacks, arthritis, and the development of amyloidosis.
- To determine the effects of long-term colchicine treatment on growth, development, and fertility in children with FMF.
Main Methods:
- A cohort of 350 children diagnosed with FMF received continuous colchicine treatment (1-2 mg/day) for 6-13 years.
- Outcomes were assessed based on remission rates of febrile attacks and arthritis.
- Adverse events, growth parameters, developmental milestones, and fertility were monitored throughout the study period.
Main Results:
- Complete remission of febrile attacks was observed in 64% of patients, with partial remission in 31%.
- Protracted arthritis attacks were virtually eliminated.
- No cases of amyloidosis were reported in children receiving colchicine; side effects were minimal and did not necessitate treatment discontinuation. Growth, development, and fertility remained normal.
Conclusions:
- Continuous, long-term colchicine prophylaxis is highly effective and safe for managing pediatric familial Mediterranean fever.
- Early diagnosis and initiation of colchicine treatment are vital for preventing disease complications like amyloidosis and ensuring normal development.
- Colchicine therapy significantly improves the quality of life for children with FMF, underscoring its role as a life-saving intervention.
Abstract:
Three hundred fifty children (younger than age 16) who had familial Mediterranean fever (FMF) were given continuous prophylactic treatment with colchicine (1-2 mg/day) for 6-13 years. Complete remission of febrile attacks was achieved in 64% of the patients, and partial remission in 31%. Protracted attacks of arthritis virtually disappeared. None of the children developed amyloidosis while on the colchicine regimen. Side effects of colchicine were insignificant, and did not prompt permanent discontinuation of treatment in any of the children. Their growth, development, and subsequent fertility were normal. The efficacy of long-term colchicine treatment of children with FMF makes early diagnosis life saving.